Chinese-American Biopharmaceutical Society (CABS) K. Fong Special Award
Dr. Gerald Chan to be Honored with CABS K. Fong Special Award - Visionary in Life Sciences
CABS Public Announcement: March 31st, 2016.
Chinese-American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that Dr. Gerald Chan is the winner of its CABS K. Fong Special Award - Visionary in Life Sciences for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies. Dr. Gerald Chan will be presented with this special award and we are honored that Dr. Chan will also be speaking at the 2016 BioPacific Conference (18th Annual Meeting of CABS) on 7th May 2016 at the San Mateo Marriott San Francisco Airport, 1770 South Amplett Blvd., San Mateo, CA 94402.
Dr. Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments. In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses (BioVex, DNAtrix), cancer vaccines (Aduro), modified cytotoxic agents (Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo). Investments in the infectious disease area include novel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Other investments cover the therapeutic areas of metabolic diseases (CVI), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognoa), and rare orphan diseases (Stealth, Apellis), as well as molecular diagnostics (ACD), drug delivery (Medtrum, Incarda) and medical devices (ViOptix, Kona, Excera). Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong.
Gerald received his BS and MS degrees in engineering from UCLA, his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health.
“CABS is very proud to honor Dr. Gerald Chan for his life-time contribution in the field of life sciences, his significant achievement towards nurturing a new generation of innovative life sciences companies and his generous support of life sciences education, including a transformative gift of $350M to the Harvard School of Public Health, the largest donation in the 380-year history of the university. ” said Dr. Jiangwen Majeti, President of CABS. “ We are very grateful to Dr. Ken Fong for his generous long-term support of this award as well as other activities at CABS throughout the year.”
About CABS K. Fong Award in Life Sciences:
CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life. Candidates must be nominated by an active member of CABS followed by review and approval of the Selection Committee. Selection criteria will be based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:
- Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or the research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the general biomedical and the CABS community and to promoting international collaboration in life sciences.
Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry, headquartered in San Francisco, California with over 3,000 members and participants. While many of our members are located in the San Francisco Bay Area, the largest biotechnology hub of the world and the birthplace of biotechnology, we also have members in other parts of the U.S. and in the Pacific Rim countries including China. Our missions include the following:
- To serve biopharmaceutical professionals of Chinese heritage or with professional interests in China, and promote professional interactions.
- To foster business opportunities and exchanges in the life science industry between the U.S. and China.
- To promote public awareness of progress and development in the pharmaceutical and biotechnological industry.
- To collaborate with other organizations in areas of mutual interest.
About Dr. Kenneth Fong:
Dr. Kenneth Fong is currently the founder and chairman of Kenson Ventures, LLC, a company that specializes in crafting development strategy for early and mid-stage stage biotech companies. Under his leadership, companies that were acquired or went public between 2007 and 2012 are: SA Biosciences (to Qiagen), DHI (to Quidel), Fermenta (to ThermoFisher), Panomics (to Affymetrix), Epitomics (to Abcam), Bioform (IPO) and Optimer (IPO). Currently, he sits on the boards of 5 biotech companies, including two biopharmaceutical, one diagnostic and two research tool company. Prior to Kenson, Ken founded and served as CEO of Clontech Laboratories (1984-1999), which was acquired by Becton Dickinson in 1999. Clontech, a leader in the life science market, was also the largest of its kind founded by an Asian American (400 people, including 65 PhD scientists) during the early years of the biotech industry. Ken served as president of Society of Chinese Bioscientists in North America (~2,000 members, 2005-09) and President of the Bay Area AAMA (1987). He was a member of the Board of Trustees of California State University (2006-2013), Board of Associates at the Whitehead Biomedical Institute at MIT and a member of the Committee of 100 (US). Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided Translational Science Awards through an endowed fund to the San Francisco State University. In addition, he has provided a number of scholarships to Peking University and the CSU students (Kenneth Fong–Hearst endowed Scholarships). In 2006, he was also involved in establishing the Fong Optometry and Medical Library at UC Berkeley and more recently an endowed professorship to Stanford University. Currently Ken spends a good amount of time cultivating and advising a number of entrepreneurs (40-55 years old group) to grow their biotech companies.
Past recipients of the K. Fong Awards include:
2015: Dr. Irving Weissman, Stanford University for his pioneering research in stem cell research.
2014: Dr. Ge Li of Wuxi Apptec for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Eli Lily, for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and Iopinavir.
2013: Dr. Peter Hirth of Plexxicon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.